Skip to main content
. Author manuscript; available in PMC: 2023 Apr 21.
Published in final edited form as: Transplant Cell Ther. 2022 Nov 25;29(3):151–163. doi: 10.1016/j.jtct.2022.11.015

Table 2.

TMA Harmonization Panel Consensus Recommended Diagnostic Criteria, Modified Jodele Criteria

Biopsy-proven disease (kidney or GI) or
Clinical criteria: must meet ≥4 of the following 7 criteria within 14 days at 2 consecutive time points
Anemia* Defined as one of the following:
1. Failure to achieve transfusion independence for pRBCs despite evidence of neutrophil engraftment
2. Hemoglobin decline from patient’s baseline by 1 g/dL
3. New onset of transfusion dependence
Rule out other causes of anemia, such as AIHA and PRCA
Thrombocytopenia* Defined as one of the following:
1. Failure to achieve platelet engraftment
2. Higher than expected platelet transfusion needs
3. Refractoriness to platelet transfusions
4. 50% reduction or greater in baseline platelet count after full platelet engraftment
Elevated LDH >ULN for age
Schistocytes Present
Hypertension >99th percentile for age (<18 yr), or systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg (≥18 yr)
Elevated sC5b-9 ≥ULN
Proteinuria ≥1 mg/mg rUPCR

pRBCs indicates packed red blood cells; AIHA, autoimmune hemolytic anemia; PRCA, pure red cell aplasia; BP, blood pressure. upper limit of normal; ULN, random urine protein to creatinine ratio (rUPCR)

*

Indicates clarification from published Jodele et al. criteria1.